Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-741-7700
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees147
OptionableOptionable
Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions
What is Global Blood Therapeutics' stock symbol?
Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."
How were Global Blood Therapeutics' earnings last quarter?
Global Blood Therapeutics Inc (NASDAQ:GBT) announced its earnings results on Tuesday, November, 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.85) by $0.02. During the same quarter last year, the firm posted ($0.66) EPS. View Global Blood Therapeutics' Earnings History.
When is Global Blood Therapeutics' next earnings date?
What price target have analysts set for GBT?
13 Wall Street analysts have issued 12 month price targets for Global Blood Therapeutics' shares. Their forecasts range from $55.00 to $150.00. On average, they anticipate Global Blood Therapeutics' share price to reach $87.3333 in the next twelve months. This suggests a possible upside of 72.8% from the stock's current price. View Analyst Price Targets for Global Blood Therapeutics.
What is the consensus analysts' recommendation for Global Blood Therapeutics?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Global Blood Therapeutics.
What are Wall Street analysts saying about Global Blood Therapeutics stock?
Here are some recent quotes from research analysts about Global Blood Therapeutics stock:
- 1. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (2/4/2019)
- 2. William Blair analysts commented, "We continue to view the stock as substantially de-risked with the completion of 24 weeks of therapy in the additional 118 enrolled patients in the Phase III HOPE study , publication of the HOPE Part A data set, and a pre-NDA meeting update in the first half as well as potential Subpart H filing in the second half as key catalysts for shares this year . We also see the company as a potential takeout candidate given the significant unmet medical need in sickle cell disease, the impressive data shown in patients with or without concomitant hydroxyurea, and the alignment of a once-daily , oral therapy dosed (potentially) in perpetuity with the large pharma commercial model. GBT remains our top pick for 2019." (1/30/2019)
- 3. Cantor Fitzgerald analysts commented, "Based on the existing clinical data, we believe voxelotor offers a compelling treatment option in SCD that lacks disease-modifying therapies. $96 price target is based on the combination of our estimate of the NPV of future cash flows from voxelotor in SCD, worth approximately $4.6 billion ($88/share), and our estimate of YE cash of $440 million ($8/share)." (10/17/2018)
- 4. HC Wainwright analysts commented, "We continue to expect voxelotor in conjunction with HU to become the standard-of-care, especially in younger patients, which could make these patients asymptomatic much like SCD-trait subjects. Our Buy rating and price target of $125 are based on a DCF analysis, derived using a beta of 1.40, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.9%, and tax rate of 15% beginning in FY 2024. We estimate approximately 70K patients in U.S., 42K patients in the $$60K (increased from $75K and $50K) U.S." (8/23/2018)
Has Global Blood Therapeutics been receiving favorable news coverage?
News articles about GBT stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Global Blood Therapeutics earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the near future.
Who are some of Global Blood Therapeutics' key competitors?
Some companies that are related to Global Blood Therapeutics include Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO), Marina Biotech (MRNA), Catalent (CTLT), Dr.Reddy's Laboratories (RDY) and Amarin (AMRN).
Who are Global Blood Therapeutics' key executives?
Global Blood Therapeutics' management team includes the folowing people:
- Dr. Ted W. Love, Pres, CEO & Director (Age 60)
- Dr. Charles J. Homcy, Founder, Advisor & Director (Age 71)
- Mr. Jeffrey S. Farrow, Chief Financial Officer (Age 57)
- Mr. Peter Radovich, Sr. VP of Operations (Age 41)
- Dr. Hing Sham, Sr. VP of Research (Age 67)
When did Global Blood Therapeutics IPO?
(GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.
Who are Global Blood Therapeutics' major shareholders?
Global Blood Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (10.39%), BlackRock Inc. (8.09%), Bank of America Corp DE (4.87%), Great Point Partners LLC (2.26%), Geode Capital Management LLC (1.19%) and Northern Trust Corp (1.17%). Company insiders that own Global Blood Therapeutics stock include Charles J Homcy, Deval L Patrick, Jung Choi, Lesley Ann Calhoun, Perceptive Advisors Llc, Peter Radovich and Robert I Tepper. View Institutional Ownership Trends for Global Blood Therapeutics.
Which major investors are selling Global Blood Therapeutics stock?
GBT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, grace capital, Casdin Capital LLC, Candriam Luxembourg S.C.A., Hudson Bay Capital Management LP, Tekla Capital Management LLC, Highbridge Capital Management LLC and MetLife Investment Advisors LLC. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Deval L Patrick, Jung Choi and Lesley Ann Calhoun. View Insider Buying and Selling for Global Blood Therapeutics.
Which major investors are buying Global Blood Therapeutics stock?
GBT stock was acquired by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Bank of America Corp DE, Dimensional Fund Advisors LP, Bank of New York Mellon Corp, Perceptive Advisors LLC, Sphera Funds Management LTD., Brown Advisory Inc. and First Midwest Bank Trust Division. View Insider Buying and Selling for Global Blood Therapeutics.
How do I buy shares of Global Blood Therapeutics?
Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Global Blood Therapeutics' stock price today?
One share of GBT stock can currently be purchased for approximately $50.55.
How big of a company is Global Blood Therapeutics?
Global Blood Therapeutics has a market capitalization of $2.64 billion. The company earns $-117,020,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. Global Blood Therapeutics employs 147 workers across the globe.
What is Global Blood Therapeutics' official website?
How can I contact Global Blood Therapeutics?
Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]
MarketBeat Community Rating for Global Blood Therapeutics (NASDAQ GBT)
MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe GBT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GBT will underperform the S&P 500 over the long term. You may vote once every thirty days.
